Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro (Q39373494)

11 September 2017

Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro (English)

1 reference

11 September 2017

1 reference

J Mani

1

1 reference

11 September 2017

S Vallo

2

1 reference

11 September 2017

K Barth

3

1 reference

11 September 2017

J Makarević

4

1 reference

11 September 2017

E Juengel

5

1 reference

11 September 2017

G Bartsch

6

1 reference

11 September 2017

C Wiesner

7

1 reference

11 September 2017

A Haferkamp

8

1 reference

11 September 2017

R A Blaheta

9

1 reference

11 September 2017

language of work or name

1 reference

27 March 2012

1 reference

Prostate Cancer and Prostatic Diseases

11 September 2017

1 reference

11 September 2017

15

1 reference

11 September 2017

3

1 reference

11 September 2017

250-255

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2012.9

11 September 2017

0 references

cites work

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.9

31 March 2020

Identifiers

DOI

10.1038/PCAN.2012.9

1 reference

11 September 2017

1 reference